Earnings/NNS for/IN most/JJS of/IN the/DT nation/NN 's/POS major/JJ pharmaceutical/JJ makers/NNS are/VBP believed/VBN *-1/-NONE- to/TO have/VB moved/VBN ahead/RB briskly/RB in/IN the/DT third/JJ quarter/NN ,/, as/IN companies/NNS with/IN newer/JJR ,/, big-selling/JJ prescription/NN drugs/NNS fared/VBD especially/RB well/RB ./.
For/IN the/DT third/JJ consecutive/JJ quarter/NN ,/, however/RB ,/, most/JJS of/IN the/DT companies/NNS '/POS revenues/NNS were/VBD battered/VBN *-1/-NONE- by/IN adverse/JJ foreign-currency/NN translations/NNS as/IN a/DT result/NN of/IN the/DT strong/JJ dollar/NN abroad/RB ./.
Analysts/NNS said/VBD that/IN Merck/NNP &/CC Co./NNP ,/, Eli/NNP Lilly/NNP &/CC Co./NNP ,/, Warner-Lambert/NNP Co./NNP and/CC the/DT Squibb/NNP Corp./NNP unit/NN of/IN Bristol-Myers/NNP Squibb/NNP Co./NNP all/DT benefited/VBD from/IN strong/JJ sales/NNS of/IN relatively/RB new/JJ ,/, higher-priced/JJ medicines/NNS that/WDT *T*-1/-NONE- provide/VBP wide/JJ profit/NN margins/NNS ./.
Less/RBR robust/JJ earnings/NNS at/IN Pfizer/NNP Inc./NNP and/CC Upjohn/NNP Co./NNP were/VBD attributed/VBN *-1/-NONE- to/TO those/DT companies/NNS '/POS older/JJR products/NNS ,/, many/JJ of/IN which/WDT *T*-2/-NONE- face/VBP stiffening/JJ competition/NN from/IN generic/JJ drugs/NNS and/CC other/JJ medicines/NNS ./.
Joseph/NNP Riccardo/NNP ,/, an/DT analyst/NN with/IN Bear/NNP ,/, Stearns/NNP &/CC Co./NNP ,/, said/VBD that/IN over/IN the/DT past/JJ few/JJ years/NNS most/JJS drug/NN makers/NNS have/VBP shed/VBN their/PRP$ slow-growing/JJ businesses/NNS and/CC instituted/VBN other/JJ cost/NN savings/NNS ,/, such/JJ as/IN *-1/-NONE- consolidating/VBG manufacturing/NN plants/NNS and/CC administrative/JJ staffs/NNS ./.
As/IN a/DT result/NN ,/, ``/`` major/JJ new/JJ products/NNS are/VBP having/VBG significant/JJ impact/NN ,/, even/RB on/IN a/DT company/NN with/IN very/RB large/JJ revenues/NNS ,/, ''/'' Mr./NNP Riccardo/NNP said/VBD 0/-NONE- *T*-1/-NONE- ./.
Analysts/NNS said/VBD 0/-NONE- profit/NN for/IN the/DT dozen/NN or/CC so/RB big/JJ drug/NN makers/NNS ,/, as/IN a/DT group/NN ,/, is/VBZ estimated/VBN *-1/-NONE- to/TO have/VB climbed/VBN between/IN 11/CD %/NN and/CC 14/CD %/NN *U*/-NONE- ./.
While/IN that/DT 's/VBZ not/RB spectacular/JJ ,/, Neil/NNP Sweig/NNP ,/, an/DT analyst/NN with/IN Prudential/NNP Bache/NNP ,/, said/VBD that/IN the/DT rate/NN of/IN growth/NN will/MD ``/`` look/VB especially/RB good/JJ as/IN */-NONE- compared/VBN *-1/-NONE- to/TO other/JJ companies/NNS if/IN the/DT economy/NN turns/VBZ downward/RB ./. ''/''
Mr./NNP Sweig/NNP estimated/VBD that/IN Merck/NNP 's/POS profit/NN for/IN the/DT quarter/NN rose/VBD by/IN about/RB 22/CD %/NN ,/, *-1/-NONE- propelled/VBN *-2/-NONE- by/IN sales/NNS of/IN its/PRP$ line-up/NN of/IN fast-growing/JJ prescription/NN drugs/NNS ,/, including/VBG its/PRP$ anti-cholesterol/JJ drug/NN ,/, Mevacor/NNP ;/: a/DT high/JJ blood/NN pressure/NN medicine/NN ,/, Vasotec/NNP ;/: Primaxin/NNP ,/, an/DT antibiotic/NN ,/, and/CC Pepcid/NNP ,/, an/DT anti-ulcer/JJ medication/NN ./.
Profit/NN climbed/VBD even/RB though/IN Merck/NNP 's/POS sales/NNS were/VBD reduced/VBN *-1/-NONE- by/IN ``/`` one/CD to/TO three/CD percentage/NN points/NNS ''/'' as/IN a/DT result/NN of/IN the/DT strong/JJ dollar/NN ,/, Mr./NNP Sweig/NNP said/VBD 0/-NONE- *T*-2/-NONE- ./.
In/IN the/DT third/JJ quarter/NN of/IN 1988/CD ,/, Merck/NNP earned/VBD $/$ 311.8/CD million/CD *U*/-NONE- ,/, or/CC 79/CD cents/NNS a/DT share/NN ./.
In/IN Rahway/NNP ,/, N.J./NNP ,/, a/DT Merck/NNP spokesman/NN said/VBD 0/-NONE- the/DT company/NN does/VBZ n't/RB make/VB earnings/NN projections/NNS ./.
Mr./NNP Sweig/NNP said/VBD 0/-NONE- he/PRP estimated/VBD that/IN Lilly/NNP 's/POS earnings/NNS for/IN the/DT quarter/NN jumped/VBD about/RB 20/CD %/NN ,/, largely/RB because/IN of/IN the/DT performance/NN of/IN its/PRP$ new/JJ anti-depressant/NN Prozac/NNP ./.
The/DT drug/NN ,/, introduced/VBD */-NONE- last/JJ year/NN ,/, is/VBZ expected/VBN *-1/-NONE- to/TO generate/VB sales/NNS of/IN about/RB $/$ 300/CD million/CD *U*/-NONE- this/DT year/NN ./.
``/`` It/PRP 's/VBZ turning/VBG out/RP *-2/-NONE- to/TO be/VB a/DT real/JJ blockbuster/NN ,/, ''/'' Mr./NNP Sweig/NNP said/VBD *T*-1/-NONE- ./.
In/IN last/JJ year/NN 's/POS third/JJ quarter/NN ,/, Lilly/NNP earned/VBD $/$ 171.4/CD million/CD *U*/-NONE- ,/, or/CC $/$ 1.20/CD *U*/-NONE- a/DT share/NN ./.
In/IN Indianapolis/NNP ,/, Lilly/NNP declined/VBD comment/NN ./.
Several/JJ analysts/NNS said/VBD 0/-NONE- they/PRP expected/VBD Warner-Lambert/NNP 's/POS profit/NN also/RB to/TO increase/VB by/IN more/JJR than/IN 20/CD %/NN from/IN $/$ 87.7/CD million/CD *U*/-NONE- ,/, or/CC $/$ 1.25/CD *U*/-NONE- a/DT share/NN ,/, 0/-NONE- it/PRP reported/VBD *T*-2/-NONE- in/IN the/DT like/JJ period/NN last/JJ year/NN ./.
The/DT company/NN is/VBZ praised/VBN *-1/-NONE- by/IN analysts/NNS for/IN *-1/-NONE- sharply/RB lowering/VBG its/PRP$ costs/NNS in/IN recent/JJ years/NNS and/CC shedding/VBG numerous/JJ companies/NNS with/IN low/JJ profit/NN margins/NNS ./.
The/DT company/NN 's/POS lean/JJ operation/NN ,/, analysts/NNS said/VBD 0/-NONE- *T*-1/-NONE- ,/, allowed/VBD sharp-rising/JJ sales/NNS from/IN its/PRP$ cholesterol/NN drug/NN ,/, Lopid/NNP ,/, to/TO power/VB earnings/NNS growth/NN ./.
Lopid/NNP sales/NNS are/VBP expected/VBN *-1/-NONE- to/TO be/VB about/RB $/$ 300/CD million/CD *U*/-NONE- this/DT year/NN ,/, up/RB from/IN $/$ 190/CD million/CD *U*/-NONE- in/IN 1988/CD ./.
In/IN Morris/NNP Plains/NNP ,/, N.J./NNP ,/, a/DT spokesman/NN for/IN the/DT company/NN said/VBD 0/-NONE- the/DT analysts/NNS '/POS projections/NNS are/VBP ``/`` in/IN the/DT ballpark/NN ./. ''/''
Squibb/NNP 's/POS profit/NN ,/, *-2/-NONE- estimated/VBN by/IN analysts/NNS *-3/-NONE- to/TO be/VB about/RB 18/CD %/NN above/IN the/DT $/$ 123/CD million/CD *U*/-NONE- ,/, or/CC $/$ 1.25/CD *U*/-NONE- a/DT share/NN ,/, 0/-NONE- it/PRP earned/VBD *T*-1/-NONE- in/IN the/DT third/JJ quarter/NN of/IN 1988/CD ,/, was/VBD the/DT result/NN of/IN especially/RB strong/JJ sales/NNS of/IN its/PRP$ Capoten/NNP drug/NN for/IN */-NONE- treating/VBG high/JJ blood/NN pressure/NN and/CC other/JJ heart/NN disease/NN ./.
The/DT company/NN was/VBD officially/RB merged/VBN *-1/-NONE- with/IN Bristol-Myers/NNP Co./NNP earlier/RBR this/DT month/NN ./.
Bristol-Myers/NNP declined/VBD *-1/-NONE- to/TO comment/VB ./.
Mr./NNP Riccardo/NNP of/IN Bear/NNP Stearns/NNP said/VBD that/IN Schering-Plough/NNP Corp./NNP 's/POS expected/JJ profit/NN rise/NN of/IN about/RB 18/CD %/NN to/TO 20/CD %/NN *U*/-NONE- ,/, and/CC Bristol-Meyers/NNP 's/POS expected/JJ profit/NN increase/NN of/IN about/RB 13/CD %/NN are/VBP largely/RB because/IN ``/`` those/DT companies/NNS are/VBP really/RB managed/VBN *-1/-NONE- well/RB ./. ''/''
ScheringPlough/NN earned/VBD $/$ 94.4/CD million/CD *U*/-NONE- ,/, or/CC 84/CD cents/NNS a/DT share/NN ,/, while/IN Bristol-Myers/NNP earned/VBD $/$ 232.3/CD million/CD *U*/-NONE- ,/, or/CC 81/CD cents/NNS a/DT share/NN ,/, in/IN the/DT like/JJ period/NN a/DT year/NN earlier/RBR ./.
In/IN Madison/NNP ,/, N.J./NNP ,/, a/DT spokesman/NN for/IN Schering-Plough/NNP said/VBD 0/-NONE- the/DT company/NN has/VBZ ``/`` no/DT problems/NNS ''/'' with/IN the/DT average/JJ estimate/NN *ICH*-1/-NONE- by/IN a/DT analysts/NNS that/IN third-quarter/JJ earnings/NNS per/IN share/NN rose/VBD by/IN about/RB 19/CD %/NN ,/, to/TO $/$ 1/CD *U*/-NONE- ./.
The/DT company/NN expects/VBZ *-1/-NONE- to/TO achieve/VB the/DT 20/CD %/NN increase/NN in/IN full-year/JJ earnings/NNS per/IN share/NN ,/, as/IN it/PRP projected/VBD in/IN the/DT spring/NN ,/, the/DT spokesman/NN said/VBD 0/-NONE- *T*-2/-NONE- ./.
Meanwhile/RB ,/, analysts/NNS said/VBD 0/-NONE- Pfizer/NNP 's/POS recent/JJ string/NN of/IN lackluster/JJ quarterly/JJ performances/NNS continued/VBD ,/, as/IN earnings/NNS in/IN the/DT quarter/NN were/VBD expected/VBN *-1/-NONE- to/TO decline/VB by/IN about/RB 5/CD %/NN ./.
Sales/NNP of/IN Pfizer/NNP 's/POS important/JJ drugs/NNS ,/, Feldene/NNP for/IN */-NONE- treating/VBG arthritis/NN ,/, and/CC Procardia/NNP ,/, a/DT heart/NN medicine/NN ,/, have/VBP shrunk/VBN because/RB of/IN increased/JJ competition/NN ./.
``/`` The/DT -LRB-/-LRB- strong/JJ -RRB-/-RRB- dollar/NN hurt/VBD Pfizer/NNP a/DT lot/NN ,/, too/RB ,/, ''/'' Mr./NNP Sweig/NNP said/VBD *T*-1/-NONE- ./.
In/IN the/DT third/JJ quarter/NN last/JJ year/NN ,/, Pfizer/NNP earned/VBD $/$ 216.8/CD million/CD *U*/-NONE- ,/, or/CC $/$ 1.29/CD *U*/-NONE- a/DT share/NN ./.
In/IN New/NNP York/NNP ,/, the/DT company/NN declined/VBD comment/NN ./.
Analysts/NNS said/VBD 0/-NONE- they/PRP expected/VBD Upjohn/NNP 's/POS profit/NN to/TO be/VB flat/JJ or/CC rise/VB by/IN only/RB about/RB 2/CD %/NN to/TO 4/CD %/NN *U*/-NONE- as/IN */-NONE- compared/VBN *-2/-NONE- with/IN $/$ 89.6/CD million/CD *U*/-NONE- ,/, or/CC 49/CD cents/NNS a/DT share/NN ,/, 0/-NONE- it/PRP earned/VBD *T*-1/-NONE- a/DT year/NN ago/RB ./.
Upjohn/NNP 's/POS biggest-selling/JJ drugs/NNS are/VBP Xanax/NNP ,/, a/DT tranquilizer/NN ,/, and/CC Halcion/NNP ,/, a/DT sedative/NN ./.
Sales/NNS of/IN both/DT drugs/NNS have/VBP been/VBN hurt/VBN *-1/-NONE- by/IN new/JJ state/NN laws/NNS restricting/VBG the/DT prescriptions/NNS of/IN certain/JJ tranquilizing/JJ medicines/NNS and/CC adverse/JJ publicity/NN about/IN the/DT excessive/JJ use/NN of/IN the/DT drugs/NNS ./.
Also/RB ,/, the/DT company/NN 's/POS hair-growing/JJ drug/NN ,/, Rogaine/NNP ,/, is/VBZ selling/VBG well/RB --/: at/IN about/RB $/$ 125/CD million/CD *U*/-NONE- for/IN the/DT year/NN ,/, but/CC the/DT company/NN 's/POS profit/NN from/IN the/DT drug/NN has/VBZ been/VBN reduced/VBN *-1/-NONE- by/IN Upjohn/NNP 's/POS expensive/JJ print/NN and/CC television/NN campaigns/NNS for/IN advertising/VBG ,/, analysts/NNS said/VBD 0/-NONE- *T*-2/-NONE- ./.
In/IN Kalamazoo/NNP ,/, Mich./NNP ,/, Upjohn/NNP declined/VBD comment/NN ./.

